Professor and Chief Otolaryngology Yale School of Medicine; Director, HandN Disease Center, Smilow Cancer Hospital; Co-Director, Molecular Virology Program, Yale Cancer Center
Otolaryngology (ENT)
Dr. Wendell G. Yarbrough, MD
|
|
Give Review
Wendell G. Yarbrough, MD works in the field of Otolaryngology (ENT). He studied medicine at University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a top medical college. University of North Carolina at Chapel Hill School of Medicine is ranked 22 in research and 2 in primary care medicine He received awards:"Top Doctors: New York Metro Area", "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer", "5-star Patient Satisfaction Awards for Overall Quality of Doctor Care", "Americas Top Physicians", "Distinguished Service Award in Scientific Programs, Exhibits, Continuing Education Courses and Instructional Course", "Jefferson Pilot Fellowship", "Resident research award", "Nathan A. Womack Scholar", "Temporal Bone Dissection Award", "Michiko Kuno Award for Best Presentation", "Deborah C. Leary Award", "Alpha Omega Alpha", "Student Research & Recognition Foundation Award", "Phi Lambda Upsilon", "Phi Beta Kappa", "Phi Eta Sigma", "John Motley Morehead Scholarship", "Fellow (FACS)", "Fellow (FAAO-HNS)", "MOREHEAD SCHOLAR" and "Harris P. Mosher Award". Wendell G. Yarbrough is a published doctor. He published 26 publications, including: 'Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study.' He is registered with Medicare and accepts Medicare payments.
Publications
- Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study.
- Characterization of HPV and host genome interactions in primary head and neck Cancers.
- Negative regulation of RelA phosphorylation: Emerging players and their roles in Cancer.
- Esophageal perforation caused by edible foreign bodies: A systematic review of the literature.
- Trends and variations in the use of adjuvant therapy for patients with head and neck Cancer.
- Public Awareness of Head and Neck Cancers: A Cross-Sectional Survey.
- Reverse-phase protein array profiling of oropharyngeal Cancer and significance of PIK3CA mutations in HPV-associated head and neck Cancer.
- Proteomic analysis of oropharyngeal Carcinomas reveals novel HPV-associated biological pathways.
- Alpha-2 Heremans Schmid Glycoprotein (AHSG) Modulates Signaling Pathways in Head and Neck Squamous Cell Carcinoma Cell Line SQ20B.
- Fus1 is a novel regulator of mitochondrial calcium handling, Ca2+-coupled mitochondrial processes and Ca2+-dependent NFAT- and NFkB-pathways in CD4+ T cells.
- A tool to determine financial impact of adverse events in health care: healthcare quality calculator.
- Conclusions about human papillomavirus-related malignancies.
- PPM1A is a RelA phosphatase with Tumor suppressor-like activity.
- AlloDerm and DermaMatrix implants for parotidectomy reconstruction: A histologic study in the rat model.
- Viable biobanking of primary head and neck squamous cell Carcinoma.
- Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell Carcinoma.
- Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCalpha invasive signaling axis.
- Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck Cancer: toxicities and efficacy.
- Downregulation of SMG-1 in HPV-positive head and neck squamous cell Carcinoma due to promoter hypermethylation correlates with improved survival.
- Complications of alloderm and dermamatrix for parotidectomy reconstruction.
- Tumor suppressor Lzap regulates cell cycle progression, doming, and zebrafish epiboly.
- LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1).
- Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell Carcinoma.
- Human-in-mouse modeling of primary head and neck squamous cell Carcinoma.
- Cellular oxidative stress response Mediates radiosensitivity in Fus1-deficient mice.
Schools
University Of North Carolina Chapel Hill School Of Medicine
University Nc School Med Hosps
University Nc School Med
University of North Carolina At Chapel Hill
Owen School Of Management Vanderbilt University
Procedures Preformed
- Cancer Surgery
- Cancer Surgery, Robotic-Assisted
- Craniectomy, Craniotomy, Surgery of Skull Base, Neuroendoscopy
- Diagnostic Nasal and-or Sinus Endoscopy
- View All
Conditions Treated
- Acute Sinusitis
- AdenoCarcinoma
- Adenoid Cystic Carcinoma
- Allergic Rhinitis
- View All
Doctors Specialties
- Ear, Nose, and Throat
- Otolaryngic Skull Base Surgery
- Otolaryngology (ENT)
Accepted Insurances
Awards
- Top Doctors: New York Metro Area
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- 5-star Patient Satisfaction Awards for Overall Quality of Doctor Care
- America’s Top Physicians
- Distinguished Service Award in Scientific Programs, Exhibits, Continuing Education Courses and Instructional Course
- Jefferson Pilot Fellowship
- Resident research award
- Nathan A. Womack Scholar
- Temporal Bone Dissection Award
- Michiko Kuno Award for Best Presentation
- Deborah C. Leary Award
- Alpha Omega Alpha
- Student Research & Recognition Foundation Award
- Phi Lambda Upsilon
- Phi Beta Kappa
- Phi Eta Sigma
- John Motley Morehead Scholarship
- Fellow (FACS)
- Fellow (FAAO-HNS)
- MOREHEAD SCHOLAR
- Harris P. Mosher Award
Education
-
University of North Carolina Hospitals -
University of North Carolina at Chapel Hill School of Medicine
Hospital
-
Yale-New Haven Hospital
Drug Facts
| NPI NUMBER | 1457448565 | |
| NPPES Provider LastName | YARBROUGH | |
| NPPES Provider FirstName | WENDELL | |
| NPPES Provider ZIPCode | 372320001 | |
| NPPES Provider State | TN | |
| Specialty Description | Otolaryngology | |
| Total Claim Count | 17.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457448565 |
| Last Name Of The Provider | YARBROUGH |
| First Name Of The Provider | WENDELL |
| View All |
Similar Doctors
|
Dr. Larry M. Marcus, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Clarence T. Sasaki, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Howard P. Boey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saral Mehra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keat-Jin Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pardis Javadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul D. Neubauer, MD |
|
|
Dr. Nicole L. Aaronson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Otremba, MD |